Rabies Immune Globulin (Monograph)

Brand names: HyperRAB S/D, Imogam Rabies-HT
Drug class: Antitoxins and Immune Globulins
ATC class: J06BB05
VA class: IM500

Medically reviewed by Drugs.com on Aug 22, 2024. Written by ASHP.

Introduction

Specific immune globulin (hyperimmune globulin). Rabies immune globulin (RIG) contains antibody to rabies antigen and is used to provide antirabies antibodies for temporary passive immunity to rabies virus. RIG commercially available in the US is prepared from plasma of donors hyperimmunized with rabies vaccine and is sometimes referred to as HRIG. Other types of RIG (e.g., equine rabies immune globulin; ERIG) may be available in other countries.

Uses for Rabies Immune Globulin

Postexposure Prophylaxis of Rabies

Postexposure prophylaxis of rabies in previously unvaccinated children, adolescents, and adults following exposure to rabies disease or virus.

Used in a postexposure prophylaxis regimen that includes active immunization with rabies vaccine and passive immunization with RIG. RIG provides immediate, temporary rabies virus-neutralizing antibodies until the patient has an immunologic response to active immunization with rabies vaccine and produces virus-neutralizing antibodies.

RIG is not included in rabies postexposure prophylaxis regimens used in individuals who previously received preexposure or postexposure regimens that included rabies vaccine. Passive immunization is not necessary in such individuals and may interfere with the desired anamnestic response to booster doses of rabies vaccine used for postexposure prophylaxis in such individuals.

Rabies is a viral infection transmitted by saliva of infected mammals, most commonly wild, terrestrial carnivores (e.g., skunks, raccoons, foxes, coyotes) or bats. In the US, the greatest risk for naturally-acquired rabies is from contact with and bites from insectivorous bats. Following exposure and infection, rabies virus usually moves along a neural pathway and enters the CNS. After entrance into the CNS, the virus is unlikely to be affected by antirabies antibodies and encephalomyelitis usually develops and almost always is fatal. In the US, approximately 16,000–39,000 individuals receive rabies postexposure prophylaxis each year. Although there were 27 rabies cases reported in the US during 2000–2008, these individuals evidently did not receive rabies postexposure prophylaxis. Rabies prevention and control strategies in the US and elimination of canine rabies virus variants and enzootic transmission among dogs have lowered the number of rabies cases in the US to an average of 1–2 per year. However, worldwide, rabies is much more common and at least 55,000 rabies-related deaths occur each year.

Whenever a possible human exposure to rabies occurs, the risk of infection must be accurately assessed to determine the need for postexposure prophylaxis. Base decisions regarding the need for postexposure prophylaxis on vaccination status of the exposed individual (see Table 1), type of exposure (bite, nonbite), information about the animal involved (type, vaccination status, condition at time of attack) (see Table 2), and rabies epidemiology in the specific geographic region. Consult local or state public health officials for assistance when evaluating rabies exposures and the need for postexposure prophylaxis.

Any person with a history of a complete preexposure or postexposure vaccination regimen with HDCV, PCECV, or rabies vaccine adsorbed (RVA; not commercially available in the US), or previous vaccination with any other type of rabies vaccine and a documented history of antibody response to the prior vaccination

Individuals with immunosuppression should receive a 5-dose regimen of rabies vaccine; give 1 mL (HDCV or PCECV) IM once on days 0, 3, 7, 14, and 28.

Deltoid area is the only acceptable site for IM administration of rabies vaccine in adults, adolescents, and older children. For younger children, deltoid or anterolateral thigh should be used. Never administer in gluteal area.

Day 0 is the day the first dose of rabies vaccine is administered.

Adapted from Use of a Reduced (4-dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010; 59 (RR-2):1-9.

Regardless of immunization status, USPHS Advisory Committee on Immunization Practices (ACIP) and AAP recommend that postexposure prophylaxis of rabies begin immediately with thorough cleansing of all bite wounds and scratches using soap and water and, if available, irrigation with a virucidal agent such as povidone-iodine solution. Local wound treatment is an essential initial step in rabies postexposure prophylaxis in all individuals. (See General under Dosage and Administration.)

In previously unvaccinated children, adolescents, and adults following potential rabies exposure, a combined regimen of active immunization with a 4- or 5-dose regimen of rabies vaccine and passive immunization with a single dose of RIG is recommended as soon as possible. (See Table 1.)

In previously vaccinated children, adolescents, and adults following potential rabies exposure, a 2-dose booster regimen of rabies vaccine (without RIG) is recommended as soon as possible. (See Table 1.)

During the 10-day observation period, begin postexposure prophylaxis in the exposed individual at the first sign of rabies in the dog, cat, or ferret that has bitten them. If the animal exhibits clinical signs of rabies, euthanize it immediately and perform appropriate testing.

Initiate postexposure prophylaxis as soon as possible following exposure to such wildlife, unless animal is available for testing and public health authorities are facilitating expeditious laboratory testing or it is already known that brain material from the animal has tested negative. Other factors that might influence urgency of decision-making regarding initiation of postexposure prophylaxis before diagnostic results are known include the animal species, general appearance and behavior of the animal, whether encounter was provoked by a human, and the severity and location of bites. Discontinue postexposure prophylaxis if appropriate laboratory tests (i.e., direct fluorescent antibody test) are negative.

Euthanize the animal and test as soon as possible. Holding for observation is not recommended.

Adapted from the Recommendations of the Advisory Committee on Immunization Practices (ACIP) on Human Rabies Prevention. MMWR Recomm Rep. 2008; 57 (RR-3):1-28.

Bite exposures include any skin penetration by teeth; all bite exposures from an animal known or suspected to be rabid, regardless of bite location, pose a potential risk of rabies transmission and require postexposure prophylaxis. Risk of transmission varies in part based on the species of biting animal, anatomic site of bite, and severity of wound. Rabies transmission can occur from bites of some animals (e.g., bats) that inflict rather minor injury and wounds that are difficult to detect.

Any potential exposure to a bat requires thorough evaluation. If possible, the bat should be submitted for rabies diagnosis. Postexposure prophylaxis is not necessary if the individual can be reasonably certain a bite, scratch, or mucous membrane exposure did not occur or if the bat is available for testing and is negative for rabies virus. Situations that might qualify as exposures include finding a bat in the same room as a person who might be unaware that a bite or direct contact has occurred (e.g., a deeply sleeping individual awakened to find a bat in the room; an adult observes a bat in the room with a previously unattended child, mentally disabled person, or intoxicated person). Other household members who do not have direct contact with the bat or were awake and aware when in the room with the bat should not be considered as having exposure to rabies.

Nonbite exposures include contamination of preexisting open wounds, abrasions, mucous membranes, or scratches with saliva or other potentially infectious material (e.g., neural tissue) from an animal known or suspected to be rabid. Although nonbite exposures only rarely cause rabies, such exposures require assessment to determine if sufficient reasons exist to consider postexposure prophylaxis. Nonbite exposures of highest risk occur in surgical recipients of corneas, solid organs, and vascular tissue transplanted from patients who died of rabies and individuals exposed to large amounts of aerosolized rabies virus.

Other forms of contact in the absence of a bite or nonbite exposure (e.g., petting a rabid animal; contact with blood, urine, or feces of a rabid animal; contact of saliva with intact skin) are not considered exposure, and postexposure prophylaxis is not necessary.

In health-care personnel, routine delivery of health care to a patient with rabies is not an indication for postexposure rabies prophylaxis. However, postexposure prophylaxis is indicated in health-care personnel if they have been bitten by the patient or if they have mucous membranes or nonintact skin (e.g., open wounds) that were contaminated with the patient's saliva or other potentially infectious material (e.g., neural tissue).

Because the rabies incubation period in humans can range from days to years (usually 1–3 months), initiate rabies postexposure prophylaxis (regardless of the length of delay) if a documented or likely exposure has occurred and clinical signs of rabies have not appeared in the exposed individual.

Postexposure prophylaxis failures have not been reported in the US when recommended immunization and wound management procedures were followed using commercially available rabies vaccines and RIG. Rare reports of failures in other countries usually involved some deviation from recommended procedures (e.g., postexposure prophylaxis not given or substantially delayed, wounds not adequately cleansed, rabies vaccine given IM into the gluteal rather than deltoid region, failure to passively immunize with RIG by infiltrating the wound site, use of less than the recommended dose of RIG, use of less than the recommended number of doses of rabies vaccine).

Travelers to rabies-endemic countries should be warned about the risk of acquiring rabies and educated in bite prevention strategies (e.g., avoiding contact with bats, avoiding stray dogs, monkeys, or cats). Because appropriate preparations of RIG or rabies vaccine may be not available for postexposure prophylaxis in the destination country, CDC recommends that travelers to such countries have a preplanned strategy in place that may involve identifying a different country where appropriate postexposure prophylaxis can be obtained if necessary. CDC states that rabies vaccines grown in animal brains (neural tissue vaccines) still may be used in some developing countries; if offered such a brain-derived vaccines (identified by a regimen that requires 5-mL injections once daily for 14–21 days), travelers should refuse the vaccine and travel to a country where an acceptable rabies vaccine preparation and RIG are available. If travelers in other countries receive postexposure prophylaxis with regimens and/or preparations not recommended by ACIP (or not used in the US), additional therapy may be necessary following return to the US. In such cases, consult state and local health authorities for advice regarding the need for additional postexposure prophylaxis. Consider serologic testing in these travelers to verify efficacy of the regimen used and to ensure an adequate immune response. (See Pre- and Postvaccination Serologic Testing under Cautions.)

Rabies Immune Globulin Dosage and Administration

General

• Rabies postexposure prophylaxis in previously unvaccinated individuals involves thorough cleansing of all bite and nonbite wounds followed by passive immunization with a single dose of RIG and active immunization with a series of 4 or 5 doses of rabies vaccine.

• RIG is not indicated for postexposure prophylaxis in individuals who previously received rabies vaccine for preexposure vaccination or postexposure prophylaxis. (See Specific Drugs under Interactions.)

• Because rabies virus may remain localized at the site of inoculation for a variable time before entering neural tissue, immediately wash all bites and scratches with soap and water; if available, irrigate with a virucidal agent (e.g., povidone-iodine solution). Institute tetanus prophylaxis and measures to control secondary infection as indicated. Consider cosmetic factors and the potential for bacterial infection before deciding to suture large wounds. AAP states that, if possible, the wound should not be sutured.

Administration

Administer by local infiltration with or without IM administration.

Do not administer IV. (See Administration Precautions under Cautions.)

Local Infiltration

Infiltrate the recommended dose of RIG into the wound(s) and surrounding area if anatomically feasible.

When the volume required to infiltrate the wound(s) exceeds the recommended dose of RIG, some clinicians recommend diluting the calculated dose in saline to yield a two- to threefold increase in solution volume to ensure that all wound areas receive adequate infiltration.

IM Administration

After infiltrating wound(s) area, administer any remaining portion of the recommended RIG dose by IM injection at a site distant from where rabies vaccine is being administered. For adults and older children, the deltoid is the only acceptable IM injection site; for younger children, the deltoid or anterolateral thigh should be used. For children with a small muscle mass, it may be necessary to administer RIG at multiple IM sites.

Do not administer RIG into gluteal area (buttock muscle) because of potential for injection-associated injury to the sciatic nerve.

Avoid injection into or near blood vessels or nerves. ACIP and AAP state that aspiration (i.e., pulling back on the syringe plunger after needle insertion and before injection) is not required because large blood vessels are not present at recommended IM injection sites.

To ensure delivery into muscle, IM injections should be made at a 90° angle to the skin using a needle length appropriate for the individual's age and body mass, the thickness of adipose tissue and muscle at the injection site, and the injection technique.

Do not administer RIG in the same syringe or simultaneously at the same injection site as rabies vaccine. (See Specific Drugs under Interactions.)

Do not mix with other immune globulins, vaccines, or solutions.

Dosage

Pediatric Patients

Postexposure Prophylaxis of Rabies

Previously Unvaccinated Children and Adolescents

Local Infiltration followed by IM

Single dose of 20 international units/kg. Infiltrate into and around area of wound(s); administer any remaining portion of the dose by IM injection. (See Administration under Dosage and Administration.)

Commercially available 2-mL vials (HyperRAB S/D, Imogam Rabies-HT) contain 300 international units of RIG (sufficient dose for a 15-kg child).

Give RIG dose as soon as possible after exposure (day 0), preferably at the time of the first dose of rabies vaccine.

If rabies vaccine is not immediately available, administer RIG and start active immunization with the vaccine as soon as possible. If RIG is not immediately available, it may be administered at any time through day 7 following the first vaccine dose; RIG is not necessary after day 7 since sufficient vaccine-induced antirabies antibody will be present in most vaccine recipients. Some experts suggest that if administration of both RIG and vaccine is delayed, both should be used regardless of the interval between exposure and prophylaxis.

Do not exceed the recommended RIG dose (i.e., single dose of 20 international units/kg); do not give repeated doses of RIG. (See Specific Drugs under Interactions.)

Adults

Postexposure Prophylaxis of Rabies

Previously Unvaccinated Adults

Local Infiltration followed by IM

Single dose of 20 international units/kg. Infiltrate into and around area of wound(s); administer any remaining portion of the dose by IM injection. (See Administration under Dosage and Administration.)

Commercially available 10-mL vials (HyperRAB S/D, Imogam Rabies-HT) contain 1500 international units of RIG (sufficient dose for a 75-kg adult).

Give RIG dose as soon as possible after exposure (day 0), preferably at the time of the first dose of rabies vaccine.

If rabies vaccine is not immediately available, administer RIG and start active immunization with the vaccine as soon as possible. If RIG is not immediately available, it may be administered at any time through day 7 following the first vaccine dose; RIG is not necessary after day 7 since sufficient vaccine-induced antirabies antibody will be present in most vaccine recipients. If administration of both RIG and vaccine is delayed, both should be used regardless of the interval between exposure and prophylaxis.

Do not exceed the recommended RIG dose (i.e., single dose of 20 international units/kg); do not give repeated doses of RIG. (See Specific Drugs under Interactions.)

Prescribing Limits

Pediatric Patients

Local Infiltration followed by IM

Maximum total dose of 20 international units/kg.

Adults

Local Infiltration followed by IM

Maximum total dose of 20 international units/kg.

Special Populations

Hepatic Impairment

No specific dosage recommendations.

Renal Impairment

No specific dosage recommendations.

Geriatric Patients

No specific dosage recommendations.

Cautions for Rabies Immune Globulin

Contraindications

• Repeated doses of RIG after active immunization with rabies vaccine is initiated. (See Specific Drugs under Interactions.)

Warnings/Precautions

Warnings

Risk of Transmissible Agents in Plasma-derived Preparations

Because RIG (HyperRAB S/D, Imogam Rabies-HT) is prepared from pooled human plasma, it is a potential vehicle for transmission of human viruses, including the causative agents of viral hepatitis and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt-Jakob disease (CJD) or variant CJD (vCJD).

Improved donor screening, viral-inactivation procedures (e.g., solvent/detergent treatment), and/or filtration procedures have reduced, but not completely eliminated, risk of pathogen transmission with plasma-derived preparations.

The manufacturing processes for RIG include certain chemical (solvent/detergent) treatment procedures and/or heat-treatment procedures to reduce viral infectious potential.

Solvent/detergent inactivation processes apparently can inactivate lipid-enveloped (e.g., hepatitis B virus [HBV], hepatitis C virus [HCV], HIV type 1 and type 2 [HIV-1 and HIV-2]), but are less effective against viruses that do not have a lipid envelope (e.g., hepatitis A virus [HAV], parvovirus B-19). Certain filtering procedures are effective in reducing levels of some enveloped and non-enveloped viruses.

Because no purification method has been shown to be totally effective in removing the risk of viral infectivity from plasma-derived preparations and because new blood-borne viruses or other disease agents may emerge that may not be inactivated by the manufacturing process or the chemical (solvent/detergent) treatment procedures currently used, administer RIG only when a benefit is expected.

Any infection believed to have been transmitted by RIG should be reported to the appropriate manufacturer.

Sensitivity Reactions

Hypersensitivity Reactions

Anaphylaxis has been reported rarely following administration of human immune globulins.

Use with caution in individuals with history of systemic allergic reactions to immune globulins.

Epinephrine and other appropriate therapy should be readily available in case anaphylaxis occurs.

Selective IgA Deficiency

HyperRAB S/D may contain IgA.

Use caution in individuals with IgA deficiency since such individuals may have serum antibodies to IgA and anaphylaxis could result following administration of preparations containing IgA. Weigh potential benefits against potential for hypersensitivity reactions.

General Precautions

Administration Precautions

Do not administer RIG in the same syringe or at the same injection site as rabies vaccine. (See Specific Drugs under Interactions.)

Do not administer IV. Inadvertent IV injection may result in serious systemic reactions; epinephrine should be available if an acute anaphylactic reaction occurs.

Individuals with Altered Immunocompetence

May be administered to individuals immunosuppressed as the result of disease or immunosuppressive therapy.

Recommendations regarding use of RIG in individuals with altered immunocompetence are the same as those for individuals who are not immunocompromised.

If rabies postexposure prophylaxis is indicated in an immunocompromised individual, serologic testing is considered essential after completion of the postexposure prophylaxis regimen to confirm than an adequate antibody response is obtained. If an adequate antibody response is not detected after the final vaccine dose of the postexposure prophylaxis series, the patient should be managed in consultation with their clinician and appropriate public health officials. (See Pre- and Postvaccination Serologic Testing under Cautions.)

Individuals with Bleeding Disorders

Because bleeding may occur following IM administration in individuals with thrombocytopenia or a bleeding disorder (e.g., hemophilia) or in those receiving anticoagulant therapy, use caution in such individuals.

ACIP states that IM injections can be used in individuals who have bleeding disorders or are receiving anticoagulant therapy if a clinician familiar with the patient's bleeding risk determines that the injection can be administered with reasonable safety. In these cases, use a fine needle (23 gauge) to administer the dose and apply firm pressure to the injection site (without rubbing) for ≥2 minutes. If patient is receiving antihemophilia therapy, administer the IM dose shortly after a scheduled dose of such therapy.

Advise the individual and/or their family about the risk of hematoma from IM injections.

Duration of Immunity

RIG provides only short-term protection against rabies. Half-life of RIG following an IM dose is approximately 21 days.

Rabies postexposure prophylaxis includes combined passive immunization with RIG and active immunization with rabies vaccine to provide effective and more prolonged immunity against rabies. Additional (booster) doses of RIG not recommended.

Pre- and Postvaccination Serologic Testing

Serologic testing is not indicated prior to postexposure prophylaxis in previously vaccinated individuals who are exposed to rabies. Such testing is inappropriate because it would delay postexposure prophylaxis and, although antirabies neutralizing antibodies are an important component of immunity, other immune effectors also play a role in disease prevention.

Serologic confirmation of rabies immunity following postexposure prophylaxis is not necessary in most individuals because of the high rate of response among immunocompetent adults, adolescents, and children when the recommended rabies postexposure regimen is used (i.e., proper wound care followed by a single dose of RIG and a 4- or 5-dose regimen of a cell culture-derived rabies vaccine).

When postexposure prophylaxis against rabies is indicated in an immunocompromised individual, serologic testing is considered essential after completion of the postexposure prophylaxis regimen to confirm that an adequate antibody response was obtained. This includes individuals receiving immunosuppressive agents (e.g., those receiving corticosteroids for the treatment of life-threatening neuroparalytic reactions to rabies vaccine). (See Individuals with Altered Immunocompetence under Cautions.)

Consider serologic testing to confirm that an adequate antibody response was obtained in travelers who received rabies postexposure prophylaxis with regimens and/or preparations not currently recommended by ACIP. (See Postexposure Prophylaxis of Rabies under Uses.)

If serologic testing for serum antirabies antibody is performed 1–2 weeks after postexposure prophylaxis is completed, ACIP defines an adequate antibody response as complete virus neutralization at a 1:5 serum dilution when determined by rapid fluorescent-focus inhibition test (RFFIT). WHO states that an enterobius antibody titer of ≥0.5 international units/mL can be considered protective.

Specific Populations

Pregnancy

Category C.

Pregnancy is not considered a contraindication for postexposure prophylaxis with RIG because of the potential risks of inadequately treated rabies exposure.

ACIP states there are no known risks for the fetus associated with use of immune globulin preparations for passive immunization of pregnant women.

Lactation

Not known whether RIG is distributed into milk or if transmission of RIG to a nursing infant would present any unusual risk.

Pediatric Use

HyperRAB S/D: Safety and efficacy not established in children.

ACIP and AAP recommend that postexposure prophylaxis (including use of RIG) in children follow the same guidelines as those in adults.

Geriatric Use

Information not available regarding differences in efficacy and safety between geriatric and younger individuals.

Common Adverse Effects

Injection site reactions (e.g., tenderness, pain, muscle soreness, stiffness), low-grade fever, headache.

Drug Interactions

Inactivated Vaccines and Toxoids

Immune globulins, including RIG, are not expected to have a clinically important effect on the immune response to inactivated vaccines or toxoids; inactivated vaccines, recombinant vaccines, polysaccharide vaccines, and toxoids may be administered simultaneously with (using different syringes and different injection sites) or at any interval before or after administration of RIG.

Live Vaccines

Antibodies present in immune globulins, including RIG, may interfere with the immune response to certain live virus vaccines (e.g., measles, mumps, and rubella virus vaccine live (MMR), rotavirus vaccine live oral, varicella virus vaccine live); these vaccines should not be administered simultaneously with or for specified intervals before or after administration of RIG. (See Specific Drugs under Interactions.) There is no evidence that immune globulin preparations interfere with the immune response to yellow fever virus vaccine live, typhoid vaccine live oral, influenza virus vaccine live intranasal, or poliovirus vaccine live oral (OPV; no longer commercially available in the US).

Specific Drugs

Rabies Immune Globulin Pharmacokinetics

Absorption

Bioavailability

Absorbed slowly following IM administration.

Following a single IM dose of 20 international units/kg, antirabies antibodies appear in serum within 24 hours and are still detectable on day 21.

Distribution

Extent

Although specific information not available, it is likely that RIG crosses the placenta since other immunoglobulins cross the placenta.

Information on distribution of RIG into milk not available; RIG may be distributed into milk since immunoglobulins (e.g., IgA, IgM, IgG) are present in colostrum.

Elimination

Half-life

Approximately 21 days following IM administration.

Stability

Storage

Parenteral

Injection

HyperRAB S/D and Imogam Rabies-HT: 2–8°C. Do not freeze; if freezing occurs, discard RIG.

HyperRAB S/D and Imogam Rabies-HT do not contain thimerosal or any other preservatives. Discard any unused portion.

Actions

• RIG commercially available in the US is a sterile, nonpyrogenic solution prepared from plasma of healthy individuals with high titers of antibody to rabies antigen (average or minimum potency 150 international units/mL).

• RIG is used to provide temporary passive immunity to rabies infection as part of a postexposure prophylaxis regimen in unvaccinated individuals exposed to rabies virus. Specific antirabies antibodies present in RIG neutralize rabies virus and inhibit the spread of the virus and its infective properties.

• Following rabies exposure and inoculation, the virus remains close to the wound for an indeterminate time and can be partially neutralized by direct contact with RIG at this site. In susceptible individuals, the virus may move along a neural pathway via the peripheral nerves toward the CNS. Following entrance into the CNS, the virus is unlikely to be affected by antibodies, and a fatal encephalomyelitis almost always develops. After clinical symptoms of rabies develop, use of RIG or rabies vaccine will not improve the prognosis; there is no specific treatment for rabies.

• Incubation period for rabies infection in humans can range from days to years (usually 1–3 months). After severe bites to the face, neck, or arms, the incubation period may be as short as 10 days.

• Development of immunity and protection from rabies infection are evaluated by appearance of antirabies antibody in serum. Minimum titers of antirabies antibodies indicating protection not definitely established to date (varies among laboratories and by type of test performed). ACIP considers antirabies antibody titers ≥1:5 as determined by RFFIT to be indicative of an adequate response to rabies immunization. WHO states that an anterobius antibody titer of ≥0.5 international units/mL can be considered protective.

• There have been no cases of rabies in the US in previously unvaccinated individuals who received the recommended postexposure prophylaxis regimen (i.e., proper wound care followed by a single dose of RIG and a 4- or 5-dose regimen of a cell culture-derived rabies vaccine).

Advice to Patients

• Advise patient and/or patient's parent or guardian of the risks and benefits of RIG.

• Advise patient and/or patient's guardian that RIG is only one component of a regimen used to prevent rabies in individuals who have been bitten, scratched, or licked on an open wound by an animal known or suspected of having rabies.

• When rabies postexposure prophylaxis is indicated in previously unvaccinated individuals, importance of receiving a single dose of RIG and completing a 4- or 5-dose series of rabies vaccine as soon as possible following rabies exposure.

• Importance of informing clinicians if the patient has altered immunocompetence because of disease (e.g., cancer, HIV/AIDS) or immunosuppressive therapy (e.g., corticosteroids, cancer treatment).

• Importance of informing clinicians if any adverse reactions (e.g., hypersensitivity reactions) occur.

• Advise patient and/or patient's parent or guardian that HyperRAB S/D and Imogam Rabies-HT are prepared from pooled human plasma. Although improved donor screening and viral-inactivating and purification procedures used in manufacture of plasma-derived preparations have reduced the risk of pathogen transmission, RIG is a potential vehicle for transmission of human viruses, including the causative agents of viral hepatitis and HIV infection, and theoretically may carry a risk of transmitting the causative agent of CJD or vCJD.

• Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, and any concomitant illnesses.

• Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.

• Importance of informing patients of other important precautionary information. (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Reload page with references included

Medical Disclaimer